Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mechanistic study of canagliflozin in type 2 diabetic kidney disease
ChiCTR2200062178Phase 4Completed
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of canagliflozin in diabetic glomerulosclerosis and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoints: Glycosylated Hemoglobin (HbA1c), Urinary Albumin-to-Creatinine Ratio (UACR) and 2 more. Started Aug 2022; status: completed.
02
Drugs
canagliflozin
03
Conditions
diabetic glomerulosclerosistype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2200062178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062178.